← All organizations
Highest phase reached
Phase 4
First clinical trial
Feb 1, 2010First marketed drug
Dec 19, 2016First NDA
Dec 19, 2016Last known activity
Dec 9, 2021
Timeline
2000s
- Jan 1, 2009
Clovis Oncology— Founded
2010s
- Nov 19, 2013
Ethical Oncology Science— Acquired
- Dec 19, 2016
rucaparib— NDA Organization
- Dec 19, 2016
rucaparib— NDA Secondary Org
Drugs by trial phase (38 distinct, 58 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (16 own, 0 via acquisition)
Phase 1 (11 own, 1 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Adenocarcinoma, Clear Cell
- Adenomyoepithelioma
- Breast Neoplasms
- Carcinoma
- Carcinoma, Endometrioid
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carcinoma, Transitional Cell
- Carcinosarcoma
- Cystadenocarcinoma, Serous
- Endometrial Neoplasms
- Esophageal Neoplasms
- Fallopian Tube Neoplasms
- Hypersensitivity
- Leiomyosarcoma
- Liver Diseases
- Lung Neoplasms
- Mesothelioma
- Mixed Tumor, Mullerian
- Neoplasm Metastasis
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Prostatic Neoplasms
- Small Cell Lung Carcinoma
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Urinary Bladder Neoplasms
Marketed drugs (1)
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (50)
- NCT05180162CollaboratorPhase 1Dec 9, 2021
- NCT04939610Lead sponsorPhase 1/Phase 2Jul 30, 2021
- NCT04676334Lead sponsorPhase 3Dec 22, 2020
- NCT04621435CollaboratorPhase 1Dec 14, 2020
- NCT04624178CollaboratorPhase 2Nov 5, 2020
- NCT04253262CollaboratorPhase 1/Phase 2Apr 30, 2020
- NCT04227522CollaboratorPhase 3Jan 31, 2020
- NCT04179396Lead sponsorPhase 1Dec 31, 2019
- NCT04151563CollaboratorPhase 1/Phase 2Dec 17, 2019
- NCT04171700Lead sponsorPhase 2Nov 30, 2019
- NCT03995017CollaboratorPhase 1/Phase 2Jul 31, 2019
- NCT04042116Lead sponsorPhase 1/Phase 2Jul 29, 2019
- NCT03992131Study directorPhase 1/Phase 2Jun 30, 2019
- NCT03992131Lead sponsorPhase 1/Phase 2Jun 30, 2019
- NCT03899155CollaboratorPhase 4Jun 28, 2019
Details
- Founded
- Boulder, CO, US Jan 1, 2009
- First NDA
- Dec 19, 2016
- Last known activity
- Dec 9, 2021
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy
- Accelerated approval